Trop-2 Induces Tumor Growth through Akt and Determines Sensitivity to Akt Inhibitors
Trop-2 and Akt expression was shown to be tightly coordinated in human breast cancers, with virtual overlap with Akt activation profiles at T308 and S473, consistent with functional interaction in vivo. Akt allosteric inhibitors were shown to only block the growth of Trop-2-expressing tumor cells, both in vitro and in preclinical models, being ineffective on Trop-2-null cells. [Clin Cancer Res] Abstract
Lysine Demethylase 2A Promotes Stemness and Angiogenesis of Breast Cancer by Upregulating Jagged1
The authors showed that expression of lysine demethylase 2A (KDM2A) is markedly increased in human breast cancer and its overexpression is associated with tumor progression and poor prognosis. Gene set enrichment analysis revealed that inhibition of KDM2A down-regulates angiogenic genes with concurrent reduction of Jagged1, NOTCH1 and HEY1 in the NOTCH signaling. [Oncotarget] Full Article
Translating Neoadjuvant Therapy into Survival Benefits: One Size Does Not Fit All
Substantial improvements in the pathological complete response rate to anti-HER2 therapy, a proposed surrogate end point for long-term clinical benefit, have been observed with neoadjuvant dual-agent HER2 blockade. Thus, it was hypothesized that this approach would provide additional survival benefits over standard-of-care therapy with the anti-HER2 antibody trastuzumab in the adjuvant setting. [Nat Rev Clin Oncol] Abstract
Treating Cancer with Selective CDK4/6 Inhibitors
Results of pivotal Phase III trials investigating palbociclib in patients with advanced-stage estrogen receptor-positive breast cancer have demonstrated a substantial improvement in progression-free survival, with a well-tolerated toxicity profile. [Nat Rev Clin Oncol] Abstract
Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Puma Biotechnology Updates Timeline for Filing New Drug Application
Puma Biotechnology, Inc. announced that based on its recent meetings with the U.S. Food and Drug Administration, the company now plans to submit its New Drug Application for the approval of neratinib for the treatment of extended adjuvant breast cancer that has previously been treated with a trastuzumab-containing regimen in mid-2016. [Puma Biotechnology, Inc.] Press Release
Recruit Top Talent: Reach more than 60,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Mammary Cell News? Click here to submit!
